Sientra and Butterfly Network Announce Strategic Partnership to Improve Diagnostic Surveillance of Breast Implant Patients
Sientra announced a strategic partnership with Butterfly Network to enhance breast implant safety through advanced ultrasound technology. This collaboration allows plastic surgeons to conduct real-time diagnostic screenings using Butterfly iQ+. Sientra, known for its innovative breast products, aims to leverage this partnership to improve patient care and safety. The integration of Butterfly iQ+ into Sientra’s education platform reinforces their commitment to quality and safety in plastic surgery.
- Partnership with Butterfly Network enhances breast implant safety.
- Integration of Butterfly iQ+ ultrasound technology for real-time patient diagnostics.
- Strengthens Sientra's safety profile with advanced imaging tools.
- None.
The partnership builds on Sientra’s safety profile by empowering surgeons with Butterfly Network’s cutting-edge point-of-care ultrasound technology to screen and evaluate patients with breast implants
SANTA BARBARA, Calif. and GUILFORD, Conn. and NEW YORK, April 30, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN), a company that offers leading transformative treatments and technologies focused on progressing the art of plastic surgery, today announced a strategic partnership with Butterfly Network, Inc. (NYSE: BFLY), a leader in point-of-care ultrasound (“POCUS”). This partnership strengthens Sientra’s strong safety profile, backed by the industry’s leading Platinum20™ warranty program, by empowering plastic surgeons to evaluate breast implant patients longitudinally using the Butterfly iQ+ and its innovative Ultrasound-on-Chip™ technology.
Breast implant surgery is one of the most frequently performed cosmetic or reconstructive surgical procedures in the United States. In recent years, ultrasound has emerged as a powerful tool for monitoring the long-term health of patients with breast implants. Through this unique partnership, Butterfly Network and Sientra are providing easy access for plastic surgeons to provide real-time, in-office diagnostic screening of their patients.
“At Sientra, patient safety and product quality remain our highest priorities, which is why we entrust our breast implants to only the most qualified surgeons in the industry,” said Ron Menezes, President and Chief Executive Officer of Sientra. “We are excited to partner with Butterfly Network to build on the long-term clinical and real-world data supporting the safety of our breast implants and equip surgeons with innovative technology to provide superior care to their patients.”
“Our partnership with Sientra highlights the ability for Butterfly iQ+ to deliver actionable and diagnostic insights as an advanced assessment tool, allowing for more informed clinical decision making, improving the patient experience,” said Dr. Todd Fruchterman, Butterfly Network’s President and Chief Executive Officer. “Sientra’s commitment to patient safety mirrors our own and complements our innovative approach to transforming care through technology. Butterfly Network’s mission is to democratize healthcare by making medical imaging accessible to everyone worldwide. With Sientra, we look forward to raising the bar in implant safety and reimagining the quality of care that patients receive.”
As part of Sientra’s commitment to safety and innovation, Butterfly iQ+ will be integrated into Sientra’s medical education platform and peer-to-peer network.
To purchase the Butterfly iQ+ ultrasound system, visit: www.sientra.com/butterfly. Butterfly iQ+ is a prescription device intended for trained and qualified healthcare professionals only.
About Sientra
Headquartered in Santa Barbara, California, Sientra is a medical aesthetics company uniquely focused on plastic surgeons. The Company mission is to offer proprietary innovations and unparalleled partnerships that radically advance how plastic surgeons think, work and care for their patients. Sientra has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company’s Breast Products Segment includes its Sientra round and shaped breast implants, the first fifth generation breast implants approved by the FDA for sale in the United States, its ground-breaking Allox2® breast tissue expander with patented dual-port and integral drain technology, and BIOCORNEUM®, the #1 performing, preferred and recommended scar gel of plastic surgeons(*).
Sientra uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Sientra is routinely posted and is accessible on the Company’s investor relations website at www.sientra.com.
*Data on file
About Butterfly Network
Founded by Dr. Jonathan Rothberg in 2011, and recently listed on the New York Stock Exchange through a business combination with Longview Acquisition Corp., Butterfly created the world's first handheld, single probe whole-body ultrasound system using semiconductor technology, the Butterfly iQ+. Butterfly’s mission is to democratize medical imaging and contribute to the aspiration of global health equity, making high-quality ultrasound affordable, easy-to-use, globally accessible, and intelligently connected, including for the 4.7 billion people around the world lacking access to ultrasound. Through its proprietary Ultrasound-on-Chip™ technology, Butterfly is paving the way for earlier detection and remote management of health conditions around the world. The Butterfly iQ+ can be purchased online today by healthcare practitioners in the United States, Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Ireland, Italy, the Netherlands, New Zealand, Norway, Poland, Portugal, Spain, Sweden, Switzerland, and the United Kingdom.
Butterfly iQ+ is a prescription device intended for trained and qualified healthcare professionals only.
Sientra, Inc. Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, based on management’s current assumptions and expectations of future events and trends, which affect or may affect Sientra’s business, strategy, operations or financial performance, and actual results may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are made only as of the date of this release. The words ‘‘believe,’’ ‘‘may,’’ ‘‘might,’’ ‘‘could,’’ ‘‘will,’’ ‘‘aim,’’ ‘‘estimate,’’ ‘‘continue, ‘‘anticipate,’’ ‘‘intend,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘position,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. Forward-looking statements may include information concerning the future popularity of breast augmentation and reconstruction procedures, the adoption of ultrasound as a diagnostic tool for breast implant patients, the ability of plastic surgeons to provide real-time, in-office diagnostic screening of breast implant patients. Such statements are subject to risks and uncertainties, including the continuing popularity of augmentation and cosmetic procedures, the Sientra’s ability to recapture delayed procedures resulting from the COVID-19 pandemic, the positive reaction from plastic surgeons and their patients to Sientra’s Breast Products, the positive reaction from plastic surgeons and patients to Sientra’s marketing, sales and educational programs, and the ability to execute on the Company’s commercial, product development and manufacturing initiatives. Additional factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Sientra’s public filings with the Securities and Exchange Commission. All statements other than statements of historical fact are forward-looking statements. The words ‘‘believe,’’ ‘‘may,’’ ‘‘might,’’ ‘‘could,’’ ‘‘will,’’ ‘‘aim,’’ ‘‘estimate,’’ ‘‘continue, ‘‘anticipate,’’ ‘‘intend,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘position,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, and such estimates, projections and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection or forward-looking statement. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in the Company’s business.
Butterfly Network, Inc. Forward Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Butterfly’s actual results may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, Butterfly’s goals and expectations with respect to its strategic partnership with Sientra, including its impact on implant safety and quality of care, and Butterfly’s development and commercialization efforts and business plans under the caption “About Butterfly Network.” These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside of Butterfly’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the impact of COVID-19 on Butterfly’s business; the ability to recognize the anticipated benefits of its business combination with Longview Acquisition Corp.; Butterfly’s ability to grow and manage growth profitably; the success, cost and timing of Butterfly’s product and service development activities; the potential attributes and benefits of Butterfly’s products and services; Butterfly’s ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; Butterfly’s ability to identify, in-license or acquire additional technology; Butterfly’s ability to maintain its existing license, manufacture, supply and distribution agreements; Butterfly’s ability to compete with other companies currently marketing or engaged in the development of products and services that Butterfly is currently marketing or developing; changes in applicable laws or regulations; the size and growth potential of the markets for Butterfly’s products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of Butterfly’s products and services and reimbursement for medical procedures conducted using its products and services; Butterfly’s estimates regarding expenses, revenue, capital requirements and needs for additional financing; Butterfly’s financial performance; Butterfly’s ability to raise financing in the future; and other risks and uncertainties indicated from time to time in Butterfly’s filings with the Securities and Exchange Commission. Butterfly cautions that the foregoing list of factors is not exclusive. Butterfly cautions you not to place undue reliance upon any forward-looking statements, which speak only as of the date of this press release. Butterfly does not undertake or accept any obligation or undertake to release publicly any updates or revisions to any forward-looking statements to reflect any change in Butterfly’s expectations or any change in events, conditions or circumstances on which any such statement is based.
Sientra Contacts:
Media
Lisa Rosas
Marketing@sientra.com
Investors
Leigh Salvo
Leigh@gilmartinir.com
Butterfly Network Contacts:
Media
Media@butterflynetinc.com
Investors
Agnes Lee
650.677.9138
alee@butterflynetinc.com
FAQ
What is the purpose of the Sientra and Butterfly Network partnership?
How does the Butterfly iQ+ technology benefit Sientra's breast implant patients?
What company operates under the stock symbol SIEN?
What specific technology is being integrated into Sientra's platform?
When was the partnership between Sientra and Butterfly Network announced?
